#mdvn

[beliyague]

⚠️⚠️¿Te has parado a pensar qué significa el juego en los niñ@s?⚠️⚠️ Es muy curioso observar que si los dejáramos libres, estarían jugando todo el día. 🎳 🧸 🪁 Muchos de nosotr@s pensamos que es una pérdida de tiempo porque lo vemos desde nuestro punto de vista, pero la verdad es que el juego es como la gasolina del niñ@. A través de él aprende y gestiona sus emociones o conflictos. Por eso podemos verles poniendo una inyección a un muñeco o imitando una situación que les ha pasado con los playmobil. Así es como organizan su psique y todo toma forma. ¿Cuántas horas al día juega tu hij@? ¿Es para tí importante que tenga tiempo para jugar? Te invito a qué observes y analices su comportamiento en el juego, te va a dar mucha información de qué piensa tu hij@ y qué cosas le preocupan. . . . . . . #juegoinfantil #tiempodejuego #juego #MDVN #crianzaconsciente #crianzarespetuosa #crianzaconapego #crianza #psicologiainfantil #educacioninfantil #escuelaparapadres #madresehijos #asesoriagratuita #crianzaconsciente #masterdarvozalniño #educaciónsingritos #educacionrespetuosa #darvozalniño #infanciafeliz (en Madrid, Spain) https://www.instagram.com/p/CbPtU8JKA3M/?igshid=NGJjMDIxMWI=

[massivewisdomgroup]

Is Pfizer About to Slash Its Dividend?

Is Pfizer About to Slash Its Dividend?

It’s no secret that Pfizer (NYSE: PFE) has been gearing up for a possible split for several years now

View On WordPress

[massive-wisdom-group]

Is Pfizer About to Slash Its Dividend?

Is Pfizer About to Slash Its Dividend?

It’s no secret that Pfizer (NYSE: PFE) has been gearing up for a possible split for several years now

View On WordPress

[investcorrectly-blog]

How Pfizer Inc. (NYSE:PFE) Makes A Comeback After It Was Written-Off?

Pfizer Inc. (NYSE:PFE) was written off after its effort to acquire Allergan and AstraZeneca failed leaving plenty of doubts about the road ahead. However, that seems to be taken care of by the company with recent acquisition of Medivation Inc (NASDAQ:MDVN) and purchase of antibiotics business from AstraZeneca. What investors were worried about? 1) Failed…

How Pfizer Inc. (NYSE:PFE) Makes A Comeback After It Was Written-Off? was originally published on InvestCorrectly.com

[investcorrectly-blog]

Mergers And Acquisitions: Medivation Inc (MDVN), Syngenta AG (ADR) (SYT), and Intersil Corp (ISIL)

U.S. stocks are expected to slew of Mergers and Acquisitions news which have been announced. Let’s look at few of them. Medivation Inc (NASDAQ:MDVN) up sharply in pre-market after Pfizer Inc. (NYSE:PFE) announced that it will acquire the biotechnology firm for $14 billion. “The proposed acquisition of Medivation is expected to immediately accelerate revenue growth…

Mergers And Acquisitions: Medivation Inc (MDVN), Syngenta AG (ADR) (SYT), and Intersil Corp (ISIL) was originally published on InvestCorrectly.com

[marketexclusive]

Market Exclusive Weekly Biotech Report Covering Sanofi SA (NYSE:SNY) FDA approval of iGlarLixi

For Our full Market Exclusive Weekly Biotech Report Click Here

Sanofi SA (NYSE:SNY)

On May 25, another FDA panel voted 12-2 in favor of approving iGlarLixi from Sanofi SA (NYSE:SNY), again surely causing Steve Jobs to make another long iRoll of his iEyes in iHeaven. Up until a few days ago the combo was called LixiLan. Sanofi, like its competitor Novo, decided to Apple-ize its combination medication in the hopes that diabetes patients would associate it with their iPhones or some such thing. We wonder if Apple has a patent on the iPrefex. If it does, both Sanofi and Novo are in deep trouble.

iGlarLixi is the same concept as iDegLira, though approval (or the recommendation of it in this case) is actually pretty important for Sanofi because the combination drug will bring some sales back to its flagging flagship insulin product Lantus. If patients want the combination drug instead of taking both separately, they’ll have to use branded Lantus instead of generic competition. We said that the stock could jump 5-10% on the news. It did jump 2.5% so far and has stayed in that range since the panel recommendation. The fact that shares have stayed in that range indicates that the recommendation for approval here was more important for Sanofi than the approval of iDegLira was for Novo Nordisk.

The main difference between the two drugs is the way the insulin is dissolved. Novo’s uses acid chain links that slowly break down. Sanofi’s glargine comes in crystallized form that slowly dissolves in the blood. Whichever one patients use just depends on personal preference and what works best for them.

Sanofi happens to be in a hostile takeover battle with Medivation Inc. (NASDAQ:MDVN) right now, as they are trying to change its entire board in order to approve their offer for the company. In the short term this is going to have a greater effect on the share price than anything coming from the direction of iGlarLixi. Still though, shares are at 2012 levels and biotech looks like it is in recovery mode. A position in Sanofi can be taken and held for the long term, and added to on any dip resulting from the situation with Medivation.

Market Exclusive Weekly Biotech Report Covering Sanofi SA (NYSE:SNY) FDA approval of iGlarLixi was originally published on Market Exclusive

[lookbeyondtheobvious-blog]